With the rates of cancer in the U.S. increasing to an expected 19 million diagnoses by 2024, many are wondering about the advancements in cancer treatment. In the Tech News Spy article “Tempus, Eric Lefkofsky, and the Rise of Data-Enabled Precision Medicine”, author Heidi Harris discusses Tempus’ paradigm shift in cancer treatment.
Despite the development of technology in electronic health records, the healthcare industry can seem behind in terms of modern technology. Eric Lefkofsky experienced this himself when his wife was diagnosed with cancer. During her treatment, they found there was a lack of digital technology to inform treatment plans, making it much more difficult to decide the best course of treatment.
After this experience, Eric Lefkofsky decided to make a change. He co-founded Tempus with the idea to create a platform that evaluates molecular and clinical data for each individual patient. With the advancements of genome sequencing, the company can provide in-depth information for each tumor. They also provide a library of clinical data and molecular information so physicians can see what treatment worked best with patients of similar molecular makeup and learn more about Eric.
As cancer research advances, experts have found that understanding the genomic data can provide clues on how to fight the disease more effectively. Tempus provides that pairing between genome sequencing with clinical information. By doing so, the company is able to help doctors create a data-enabled treatment plan with the hopes of creating more effective treatment plans for each individual.
By pairing the treatments with the cancer treatment, doctor’s will likely be able to determine which treatments and medicines are more likely to work. The library is continuously updated and provides real-time access to the information, allowing doctors to make immediate decisions regarding treatment and more information click here.
Eric Lefkofsky is a leading member of Chicago’s elite. He is not only on the board of the Art Institute of Chicago, the Children’s Hospital, and World Business Chicago, but he is also a Trustee of the Steppenwolf Theatre company and a dedicated philanthropist.
He also seeks to spread his knowledge through teaching. He is an Adjunct Professor at the Booth School of Business in the University of Chicago. There he teaches courses on technology based-business and entrepreneurship. He has also taught at DePaul University and Northwestern University and Eric’s lacrosse camp.